← All trials
NCT07013123
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2025
- Primary completion
- Aug 18, 2029
- Completion date
- Aug 18, 2029
- First posted
- Jun 10, 2025
- Last posted
- Jun 10, 2025
- Enrollment
- 38
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MontpellierLead sponsor
- AstraZenecaCollaborator
- ALK-Abello, S.A.Collaborator
- University of MontpellierOfficial
- University of NimesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.